Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

Amendment No. 1 to Draft Registration Statement

Webfonts: Making Wikimedia projects readable for everyone

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Security Solutions Today: Jul-Aug 2020 by Security Solutions Today - Issuu

424B4

February 2016 DC Beacon by The Beacon Newspapers - Issuu

S-1

Motley Fool: Smart shopping, how dumb is it to gamble and this week's trivia

Check out these new features and extensions kicked off at Google Summer of Code 2015

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors